New Data Show That Intercept Blood System Inactivates Virus in Same Viral Family as SARS
As I have said before IMO SARS was the 2nd attempt to Weaponize then release into GenPop an actual BioWeapon for trials and testing. Now in “Infection Control” magazine they have backed my long held premise of SARS and Corona Virus being one and the same ‘family’ of viruses that share many characteristics, genes and other Medical Entomological traits. This is the implication article that explains “they” were Investigating both SARS and CORONA all the way back to 2003!
June 24, 2003
Personal Protective Equipment, Archive, Viral, Infections, Clinical Interventions
BRUSSELS, Belgium — Preliminary test results demonstrate that pathogen inactivation technology is effective against the human coronavirus
Subsidiaries of Baxter International Inc. and Cerus Corporation announce preliminary test results demonstrating that the INTERCEPT Blood System for platelets inactivates one of the human strains of coronavirus, a representative member of the viral family that includes the causative agent of SARS (Severe Acute Respiratory Syndrome). The preliminary results demonstrate that this new blood safety technology is capable of inactivating coronavirus in blood products.
Currently, SARS has infected almost 8.000 people worldwide and has a mortality rate of 15 percent and up to 50 percent in elderly patients. This coronavirus has been detected in the blood of infected patients during the acute phase of the illness, and it is therefore suspected that the virus is transmissible through blood. The current strategies in place to prevent the spread of the coronavirus through blood transfusions include a worldwide donor deferral program instituted by the World Health Organization (WHO) and research surrounding test development to enable screening and detection.
The in-vitro study measured the inactivation level of the INTERCEPT Blood System against a lipid-enveloped, single-stranded RNA virus of the coronavirus family. The 229E strain of coronavirus, an isolate that causes respiratory illness in humans, was used in this study. Following the inactivation procedure, the solution was tested for residual viable virus. Results of this preliminary study show that the virus was inactivated below the limit of detection in the assay system used (i.e., no viable virus was detected after treatment). Cerus and Baxter are pursuing options for collaborative studies to demonstrate inactivation of the SARS agent… https://www.infectioncontroltoday.com/personal-protective-equipment/new-data-show-intercept-blood-system-inactivates-virus-same-viral